Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Larkin, James; Chiarion‐Sileni, Vanna; González, René; Grob, Jean‐Jacques; Rutkowski, Piotr; D. Lao, Christopher; Lance Cowey, C.; Schadendorf, Dirk; Wagstaff, John; Dummer, Reinhard; Francesco Ferrucci, Pier; Smylie, Michael; Hogg, David; F. Hill, Andrew; Márquez‐Rodas, Iván; B.A.G. Haanen, John; Guidoboni, Massimo; Maio, Michele; Schöffski, Patrick; S. Carlino, Matteo; Lebbé, Célèste; A. McArthur, Grant; A. Ascierto, Paolo; A. Daniels, Gregory; V. Long, Georgina; Bastholt, Lars; I. Rizzo, Jasmine; Balogh, Ágnes; Moshyk, Andriy; Stephen Hodi, F.; D. Wolchok, Jedd

doi:10.1056/nejmoa1910836

Public

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Published in New England Journal of Medicine • Sep 28, 2019

Authors:

James Larkin

Vanna Chiarion‐Sileni

René González

Abstract

BACKGROUND Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advanced melanoma. We now report 5-year outcomes in the trial. METHODS We randomly assigned patients with previously untreated adv...

Subject

Ipilimumab

Nivolumab

Melanoma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!